73027-79-9

Basic information

• Product Name: 4,6-Dichloronicotinic acid
• Synonyms: 2,4-DICHLORO-5-PYRIDINE-5-CARBOXYLIC ACID;2,4-DICHLORO-5-CARBOXYLPYRIDINE;2,4-DICHLOROPYRIDINE-5-CARBOXYLIC ACID;4,6-DICHLORONICOTINIC ACID;4,6-DICHLOROPYRIDINE-3-CARBOXYLIC ACID;2,4-Dichloro-5-carboxypyridine;2,4-Dichloro-5-pyridinecarboxylic acid;2,4-Dichloro-5-carboxylpyridine ,97%
• CAS NO: 73027-79-9
• Molecular Formula: C₆H₃Cl₂NO₂
• Molecular Weight: 192
• EINECS: -0
• Product Categories: Pyridine;Pyridines
• Mol File: 73027-79-9.mol
• Article Data: 22

Chemical Properties

• Melting Point: 158-160
• Boiling Point: 336.997 °C at 760 mmHg
• Flash Point: 157.61 °C
• Appearance: /Solid
• Density: 1.612 g/cm³
• Vapor Pressure: 4.23E-05mmHg at 25°C
• Refractive Index: 1.605
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 1.87±0.25(Predicted)
• Water Solubility: Slightly soluble in water.
• CAS DataBase Reference: 4,6-Dichloronicotinic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4,6-Dichloronicotinic acid(73027-79-9)
• EPA Substance Registry System: 4,6-Dichloronicotinic acid(73027-79-9)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22-20/21/22
• Safety Statements: 24/25-36/37
• HazardClass: IRRITANT
• Hazardous Substances Data: 73027-79-9(Hazardous Substances Data)

Usage

Chemical Properties

White solid

Uses

4,6-Dichloronicotinic acid is an important raw material and intermediate used in organic synthesis, pharmaceuticals, agrochemicals and dyestuff fields.

InChI:InChI=1/C6H3Cl2NO2/c7-4-1-5(8)9-2-3(4)6(10)11/h1-2H,(H,10,11)

Upstream product

• 40296-46-6 ethyl 4,6-dichloronicotinate 
• 6975-44-6 4,6-dihydroxynicotinic acid ethyl ester 
• 105-50-0 diethyl 1,3-acetonedicarboxylate 
• 1830-54-2 3-oxopentanedioic acid dimethyl ester 
• 79398-27-9 methyl 4,6-dihydroxypyridine-3-carboxylate 
• 65973-52-6 methyl 4,6-dichloropyridine-3-carboxylate 
• 343781-36-2 2,4-dichloro-3-iodo-pyridine 
• 78607-36-0 2-chloro-3-iodopyridine 
• 153034-86-7 2-chloro-4-iodopyridine 
• 26452-80-2 2,4-dichloropyridine 
• 109-09-1 2-chloropyridine 
• 124-38-9 carbon dioxide 
• 343781-49-7 2,4-dichloro-5-iodopyridine 

Downstream Products

• 166526-03-0 4,6-dichloropyridine-3-carbonitrile 
• 107836-75-9 4,6-dichloropyridine-3-carbonyl chloride 
• 55934-01-5 2,3,5-trichloropyridine 
• 847608-22-4 4-(4-bromo-2-chlorophenylamino)-6-chloronicotinic acid hydrochloride salt 
• 70593-57-6 4,6-dichloro-nicotinamide 
• 1040246-72-7 6-dichloro-4-(2-fluoro-4-iodophenylamino)nicotinic acid 
• 847373-07-3 4-(4-bromo-2-chloro-phenylamino)-6-chloro-nicotinic acid 
• 1093955-77-1 C₁₆H₁₆ClNO₄ 
• 716362-10-6 6-chloro-4-methoxypyridine-3-carboxylic acid 
• 862170-57-8 4-[(4,6-dichloro-3-pyridinyl)carbonyl]benzonitrile 
• 862170-55-6 (4,6-dichloro-3-pyridinyl)(4-fluorophenyl)methanone 
• 862170-51-2 (4,6-dichloro-3-pyridinyl)-[4-(methyloxy)phenyl]methanone 
• 1540715-31-8 C₁₄H₈Cl₂F₂O 
• 1254216-71-1 6-(4-fluoro-3-(pyrrolidine-1-carboxamido)phenylamino)-4-(pyridin-3-ylmethylamino)nicotinamide 

Relevant articles and documents

Synthesis and SAR studies of novel 1,2,4-oxadiazole-sulfonamide based compounds as potential anticancer agents for colorectal cancer therapy

A diverse series of 1,2,4-oxadiazoles based substituted compounds were designed, synthesized and evaluated as anticancer agents targeting carbonic anhydrase IX (CAIX). Initial structure-activity analysis suggested that the thiazole/thiophene-sulfonamide conjugates of 1,2,4-oxadiazoles exhibited potent anticancer activities with low μM potencies. Compound OX12 exhibited antiproliferative activity (IC50 = 11.1 μM) along with appreciable inhibition potential for tumor-associated CAIX (IC50 = 4.23 μM) isoform. Therefore, OX12 was structurally optimized and its SAR oriented derivatives (OX17-27) were synthesized and evaluated. This iteration resulted in compound OX27 with an almost two-fold increase in antiproliferative effect (IC50 = 6.0 μM) comparable to the clinical drug doxorubicin and significantly higher potency against CAIX (IC50 = 0.74 μM). Additionally, OX27 treatment decreases the expression of CAIX, induces apoptosis and ROS production, inhibited colony formation and migration of colon cancer cells. Our studies provide preclinical rational for the further optimization of identified OX27 as a suitable lead for the possible treatment of CRC.

Discovery and structure-based design of 4,6-diaminonicotinamides as potent and selective IRAK4 inhibitors

The identification of small molecule inhibitors of IRAK4 for the treatment of autoimmune diseases has been an area of intense research. We discovered novel 4,6-diaminonicotinamides which potently inhibit IRAK4. Optimization efforts were aided by X-ray crystal structures of inhibitors bound to IRAK4. Structure activity relationship (SAR) studies led to the identification of compound 29 which exhibited sub-micromolar potency in a LTA stimulated cellular assay.

HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS

Disclosed are compounds of Formula (I) Formula(I) or salts thereof, wherein HET is a heteroaryl selected from oxazolyl, pyrazolyl, imidazo[l,2-b]pyridazin-3-yl, and pyrazolo[l,5-a]pyrimidin-3-yl, wherein said heteroaryl is attached to the pyridinyl group in the compound of Formula (I) by a carbon ring atom in the heteroaryl and wherein said heteroaryl is substituted with zero to 2 Rb; and R1, R3, and Rb are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.